Top

Published in:

01-10-2015 | Original Article

Renal cell carcinoma and tumour thrombus in the inferior vena cava: clinical outcome of 98 consecutive patients and the prognostic value of preoperative parameters

Authors: Christian Niedworok, Bettina Dörrenhaus, Frank vom Dorp, Jarowit Adam Piotrowski, Stephan Tschirdewahn, Tibor Szarvas, Herbert Rübben, Marcus Schenck

Published in: World Journal of Urology | Issue 10/2015

Abstract

Objectives

To evaluate the outcome of patients after nephrectomy and removal of tumour thrombus and to assess the prognostic value of preoperative parameters.

Patients and methods

Ninety-eight patients who were surgically treated between 2002 and 2011 were included. Patients’ charts were reviewed, and patients with renal cell carcinoma (RCC) and concomitant tumour thrombus in the renal vein (RV) were compared with those with extended inferior vena cava (IVC) thrombus. Wilcoxon rank-sum test, Kaplan–Meier analysis and uni- and multivariate Cox regression analysis were used for statistical evaluation.

Results

Follow-up was 36 months (20–122 months), and 5-year disease-specific survival (DSS) and overall survival were 68.4 and 54.1 %, respectively. Patients with extended thrombus (levels 2–4) had higher intraoperative transfusion rates of concentrated red cells (CRC) and fresh-frozen plasma (FFP) compared with patients with thrombus confined to the RV (CRC: 5.8 vs. 1.5, p < 0.0001; FFP: 2.3 vs. 0.4, p = 0.0032). Surgery time (190 vs. 107 min, p < 0.0001), duration of hospitalisation (16 vs. 11 days, p = 0.0269), serum phosphate (3.64 vs. 3.29 mmol/l, p = 0.0369) and CRP levels (6.7 vs. 4.4 mg/dl, p = 0.0194) as well as aPTT were increased (33.7 vs. 29.6 s, p = 0.0059) in extended thrombus disease. In multivariate analysis, the presence of distant metastasis (p = 0.03) and lymphovascular invasion (p = 0.001), high platelet counts (p = 0.001) and high serum potassium levels (p = 0.032) proved to be independent prognostic factors.

Conclusion

The surgical treatment of RCC with tumour thrombus in the RV or IVC has favourable results. Extended thrombus disease requires multidisciplinary approach. High serum potassium levels and platelet counts are associated with reduced DSS.

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013. http://globocan.iarc.fr

Haferkamp A, Bastian PJ, Jakobi H, Pritsch M, Pfitzenmaier J, Albers P, Hallscheidt P, Müller SC, Hohenfellner M (2007) Renal cell carcinoma with tumour thrombus extension into the vena cava: prospective long-term followup. J Urol 177(5):1703–1708CrossRefPubMed

Rigaud J, Hetet JF, Braud G, Battisti S, Le Normand L, Glemain P, Karam G, Bouchot O (2006) Surgical care, morbidity, mortality and follow-up after nephrectomy for renal cancer with extension of tumour thrombus into the inferior vena cava: retrospective study since 1990s. Eur Urol 50(2):302–310CrossRefPubMed

Neves RJ, Zincke H (1987) Surgical treatment of renal cancer with vena cava extension. Br J Urol 59(5):390–395CrossRefPubMed

Klatte T, Pantuck AJ, Riggs SB, Kleid MD, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS (2007) Prognostic factors for renal cell carcinoma with tumour thrombus extension. J Urol 178(4 Pt 1):1189–1195 (discussion 1195)CrossRefPubMed

Lambert EH, Pierorazio PM, Shabsigh A, Olsson CA, Benson MC, McKiernan JM (2007) Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumour thrombus. Urology 69(6):1054–1058CrossRefPubMed

Casey RG, Raheem OA, Elmusharaf E, Madhavan P, Tolan M, Lynch TH (2013) Renal cell carcinoma with IVC and atrial thrombus: a single centre’s 10 year surgical experience. Surgeon 11(6):295–299. doi:10.1016/j.surge.2013.02.007 CrossRefPubMed

Sidana A, Goyal J, Aggarwal P, Verma P, Rodriguez R (2012) Determinants of outcomes after resection of renal cell carcinoma with venous involvement. Int Urol Nephrol 44(6):1671–1679. doi:10.1007/s11255-012-0314-x CrossRefPubMed

Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H (2004) The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 94(1):33–41CrossRefPubMed

10.

Kuczyk MA, Bokemeyer C, Köhn G, Stief CG, Machtens S, Truss M, Höfner K, Jonas U (1997) Prognostic relevance of intracaval neoplastic extension for patients with renal cell cancer. Br J Urol 80(1):18–24CrossRefPubMed

11.

Sweeney P, Wood CG, Pisters LL, Slaton JW, Vaporciyan A, Munsell M, Carpenter S, Putnam J, Swisher SG, Walsh G, Swanson D, Dinney CP (2003) Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol 21(5):327–333CrossRefPubMed

12.

Cho MC, Kim JK, Moon KC, Kim HH, Kwak C (2013) Prognostic factor for Korean patients with renal cell carcinoma and venous tumour thrombus extension: application of the new 2009 TNM staging system. Int Braz J Urol 39(3):353–363. doi:10.1590/S1677-5538.IBJU.2013.03.08 CrossRefPubMed

13.

Schneider M, Hadaschik B, Hallscheidt P, Jakobi H, Fritz M, Motsch J, Pahernik S, Hohenfellner M (2013) Manual repositioning of intra-atrial kidney cancer tumour thrombus: a technique reducing the need for cardiopulmonary bypass. Urology 81(4):909–914. doi:10.1016/j.urology.2012.10.064 CrossRefPubMed

14.

Ciancio G, Shirodkar SP, Soloway MS, Livingstone AS, Barron M, Salerno TA (2010) Renal carcinoma with supradiaphragmatic tumour thrombus: avoiding sternotomy and cardiopulmonary bypass. Ann Thorac Surg 89(2):505–510. doi:10.1016/j.athoracsur.2009.11.025 CrossRefPubMed

15.

Bertini R, Roscigno M, Freschi M, Strada E, Angiolilli D, Petralia G, Matloob R, Sozzi F, Capitanio U, Da Pozzo LF, Colombo R, Guazzoni G, Cremonini A, Montorsi F, Rigatti P (2011) Impact of venous tumour thrombus consistency (solid vs friable) on cancer-specific survival in patients with renal cell carcinoma. Eur Urol 60(2):358–365. doi:10.1016/j.eururo.2011.05.029 CrossRefPubMed

16.

Coons BJ, Stec AA, Stratton KL, Chang SS, Cookson MS, Duke Herrell S, Smith JA Jr, Clark PE (2009) Prognostic factors in T3b renal cell carcinoma. World J Urol 27(1):75–79. doi:10.1007/s00345-008-0358-9 PubMedCentralCrossRefPubMed

17.

Yap SA, Horovitz D, Alibhai SM, Abouassaly R, Timilshina N, Finelli A (2012) Predictors of early mortality after radical nephrectomy with renal vein or inferior vena cava thrombectomy—a population-based study. BJU Int 110(9):1283–1288. doi:10.1111/j.1464-410X.2012.11125.x CrossRefPubMed

18.

Iwasaki A, Hamanaka W, Harnada T, Maekawa S, Enatsu S, Shirakusa T (2007) Significance of platelet counts in patients who underwent surgical treatment for lung metastasis. Int Surg 92(2):103–109PubMed

19.

Moschini M, Suardi N, Pellucchi F, Rocchini L, La Croce G, Capitanio U, Briganti A, Damiano R, Montorsi F, Colombo R (2014) Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma. Anticancer Res 34(6):3225–3230PubMed

20.

Jensvoll H, Blix K, Brækkan SK, Hansen JB (2014) Platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the Tromsø Study. PLoS One 9(3):e92011. doi:10.1371/journal.pone.0092011 eCollection 2014PubMedCentralCrossRefPubMed

21.

Simanek R, Vormittag R, Ay C, Alguel G, Dunkler D, Schwarzinger I, Steger G, Jaeger U, Zielinski C, Pabinger I (2010) High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 8(1):114–120. doi:10.1111/j.1538-7836.2009.03680.x CrossRefPubMed

22.

Feng JF, Huang Y, Lu WS, Chen QX (2013) Preoperative platelet count in esophageal squamous cell carcinoma: is it a prognostic factor? Langenbecks Arch Surg 398(8):1115–1122. doi:10.1007/s00423-013-1111-4 CrossRefPubMed

23.

Karpatkin S, Ambrogio C, Pearlstein E (1988) The role of tumour-induced platelet aggregation, platelet adhesion and adhesive proteins in tumour metastasis. Prog Clin Biol Res 283:585–606PubMed

24.

Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, Sood AK, Afshar-Kharghan V (2012) Platelets increase the proliferation of ovarian cancer cells. Blood 120(24):4869–4872. doi:10.1182/blood-2012-06-438598 PubMedCentralCrossRefPubMed

25.

Kerr BA, Miocinovic R, Smith AK, Klein EA, Byzova TV (2010) Comparison of tumour and microenvironment secretomes in plasma and in platelets during prostate cancer growth in a xenograft model. Neoplasia 12(5):388–396PubMedCentralCrossRefPubMed

26.

Ho-Tin-Noé B, Goerge T, Wagner DD (2009) Platelets: guardians of tumour vasculature. Cancer Res 69(14):5623–5626. doi:10.1158/0008-5472.CAN-09-1370 CrossRefPubMed

27.

Toral C, Mendoza-Garrido ME, Azorín E, Hernández-Gallegos E, Gomora JC, Delgadillo DM, Solano-Agama C, Camacho J (2007) Effect of extracellular matrix on adhesion, viability, actin cytoskeleton and K+ currents of cells expressing human ether à go-go channels. Life Sci 81(3):255–265CrossRefPubMed

28.

Weber C, Mello de Queiroz F, Downie BR, Suckow A, Stühmer W, Pardo LA (2006) Silencing the activity and proliferative properties of the human EagI potassium channel by RNA interference. J Biol Chem 281(19):13030–13037CrossRefPubMed

29.

Gavrilova-Ruch O, Schönherr K, Gessner G, Schönherr R, Klapperstück T, Wohlrab W, Heinemann SH (2002) Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. J Membr Biol 188(2):137–149CrossRefPubMed

30.

Weaver AK, Liu X, Sontheimer H (2004) Role for calcium-activated potassium channels (BK) in growth control of human malignant glioma cells. J Neurosci Res 78(2):224–234PubMedCentralCrossRefPubMed

Title: Renal cell carcinoma and tumour thrombus in the inferior vena cava: clinical outcome of 98 consecutive patients and the prognostic value of preoperative parameters
Authors: Christian Niedworok
Bettina Dörrenhaus
Frank vom Dorp
Jarowit Adam Piotrowski
Stephan Tschirdewahn
Tibor Szarvas
Herbert Rübben
Marcus Schenck
Publication date: 01-10-2015
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 10/2015
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-014-1449-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Renal cell carcinoma and tumour thrombus in the inferior vena cava: clinical outcome of 98 consecutive patients and the prognostic value of preoperative parameters

Abstract

Objectives

Patients and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2015

Prostate histoscanning true targeting guided prostate biopsy: initial clinical experience

Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity

Phosphodiesterase type 2 distribution in the guinea pig urinary bladder

Flow matters 2: How to improve irrigation flow in small-calibre percutaneous procedures—the purging effect

Quality of life outcomes after radical cystectomy: long-term standardized assessment of Studer Pouch versus I-Pouch

Hand-assisted laparoscopic bladder cuff excision via the same hand port as that used for nephroureterectomy